Malignant Breast Tumor
Conditions
Interventions
Training group:None
Test group:None
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
Female
Age
20 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed as breast cancer according to the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3); 2. Female breast cancer patients aged 20 years or older who were diagnosed with de novo liver metastasis between 2000 and 2021; 3. De novo liver metastasis (liver metastasis present at the time of diagnosis, not subsequent recurrent metastasis); 4. Known American Joint Committee on Cancer (AJCC) staging (specifically Stage IV, as de novo liver metastasis falls into the category of Stage IV breast cancer); 5. Visceral metastasis status: Known presence or absence of other visceral metastases (e.g., brain, lung metastases, etc.); 6. Having active follow-up records (not lost to follow-up or without follow-up information); 7. Having valid survival time (clear time from diagnosis to outcome) and survival status (alive/dead); 8. Known breast cancer molecular subtype (HR?/HER2?, HR?/HER2?, HR?/HER2?, triple-negative/HR?/HER2?); 9. Known surgical status of the primary tumor (whether the patient received surgery for the primary tumor); 10. Known cause of death (excluding cases diagnosed only through autopsy/death certificate without recorded cause of death).
Exclusion criteria
Exclusion criteria: 1. Patients with other malignant comorbidities were excluded; 2. Patients with occult breast cancer (Stage T0, i.e., primary tumor cannot be evaluated or detected) were excluded; 3. Patients with unclear T stage (primary tumor size/invasion range) and N stage (regional lymph node metastasis status) were excluded; 4. Patients with unclear molecular subtype (HR and HER2 expression statuses) were excluded; 5. Patients with unclear histological grade (degree of tumor differentiation) were excluded; 6. Patients with unclear treatment information (e.g., status of primary tumor surgery, chemotherapy, and radiotherapy) were excluded; 7. Patients diagnosed only through autopsy or death certificate were excluded, as such patients lack complete clinical follow-up records.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Nomogram Risk Score and Risk Stratification Outcomes; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-/3-/5-Year Overall Survival Rate;Hazard Ratio (HR) for Mortality and 95% Confidence Interval (95% CI);Subgroup Survival Difference Indicators; | — |
Countries
China
Contacts
Public ContactHou Lingmi
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed